The global BCI race has, until now, been a two-player game. The United States builds the implants. China writes the five-year plans. Everyone else watches.
India just stepped onto the field. The Indian Institute of Science (IISc) in Bangalore has launched a moonshot project to build AI-powered brain co-processors for stroke rehabilitation — a system that would decode neural signals and adapt in real time as a patient’s brain rewires itself during recovery. It’s not a chip-in-the-skull play. It’s a bet that India’s deep bench of AI and signal processing talent can be pointed at one of neurology’s hardest problems.
The choice of target is strategic. Stroke is the fourth leading cause of death in India, and the country’s rehabilitation infrastructure thins out fast beyond the big cities. A portable, AI-driven BCI system that doesn’t require a neurologist on-site could reach patients who currently have nothing. India’s version of neurotechnology may not look like Neuralink’s — it might look like a device designed for a district hospital in Madhya Pradesh rather than a lab in Fremont.
The bigger picture is geopolitical. China has poured billions into brain science — roughly $750 million through the China Brain Project’s last five-year allocation alone, plus a separate $165 million Shenzhen fund specifically for BCI commercialization, and it has designated brain-computer interfaces as one of six priority industries in the current five-year plan. The US has Neuralink, Synchron, Paradromics, Precision Neuroscience, and decades of DARPA-funded research behind them. Europe has CorTec putting implants in patients. India has IISc, a handful of IIT labs with active neural engineering programs, and — critically — no regulatory pathway for brain-computer interface devices, no dedicated neurotech funding, and no national strategy.
What India does have is leverage it hasn’t used yet. The country’s pharmaceutical and medical device manufacturing base is among the largest in the world. Its AI talent pool is deep. And its healthcare system serves 1.4 billion people, many of whom will never afford a $50,000 implant — creating a market incentive for low-cost, scalable neurotechnology that no Western company is currently building for.
The argument that analysts in Delhi and Bangalore are now making is simple: India can design its own neurotech ecosystem or import someone else’s. The IISc moonshot suggests that at least a few people in the right rooms understand the difference. Whether that awareness translates into funding, regulation, and a real industrial pipeline is the question that will determine whether India becomes a BCI player or a BCI customer.